Mease: Filgotinib (selective JAK1i) in active PsA ph2. Promising data. Interesting and informative way to present individual participant level data over time rather than just aggregate data - may be more useful for clinicians and patients to understand. #EULAR2019 @RheumNow https://t.co/B0pLODWGJ9